377 related articles for article (PubMed ID: 8058057)
21. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
22. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells.
Ritke MK; Rusnak JM; Lazo JS; Allan WP; Dive C; Heer S; Yalowich JC
Mol Pharmacol; 1994 Oct; 46(4):605-11. PubMed ID: 7969039
[TBL] [Abstract][Full Text] [Related]
23. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
24. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
25. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
26. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
27. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
28. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
[TBL] [Abstract][Full Text] [Related]
29. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
31. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
Yu Q; Mirski SE; Sparks KE; Cole SP
Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
[TBL] [Abstract][Full Text] [Related]
32. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
33. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line.
Webb CD; Latham MD; Lock RB; Sullivan DM
Cancer Res; 1991 Dec; 51(24):6543-9. PubMed ID: 1660341
[TBL] [Abstract][Full Text] [Related]
34. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
[TBL] [Abstract][Full Text] [Related]
35. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
Chen M; Beck WT
Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
[TBL] [Abstract][Full Text] [Related]
36. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
37. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.
Ritke MK; Yalowich JC
Biochem Pharmacol; 1993 Dec; 46(11):2007-20. PubMed ID: 8267650
[TBL] [Abstract][Full Text] [Related]
38. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
39. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
[TBL] [Abstract][Full Text] [Related]
40. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R
Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
